Evidence map›Paper›PMID 41615512›Full record

ArticleJournal of neurology2026

Short-term memory conjunctive binding in subjective cognitive decline: A PET biomarker-based study.

M A Cecchini, A Studart-Neto, N C Moraes, C G Carneiro, A C Gomes, C A Buchpiguel, S M D Brucki, A M Coutinho, R Nitrini, M S Yassuda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M A Cecchini *Human Cognitive Neuroscience, Psychology, University of Edinburgh, Edinburgh, UK. mario.cecchini@ed.ac.uk.ORCID http://orcid.org/0000-0001-5853-3422
A Studart-Neto *Department of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.
N C MoraesDepartment of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.
C G CarneiroLaboratory and Division of Nuclear Medicine (LIM-43), Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo, Brazil.
A C GomesLaboratory and Division of Nuclear Medicine (LIM-43), Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo, Brazil.
C A BuchpiguelLaboratory and Division of Nuclear Medicine (LIM-43), Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo, Brazil.
S M D BruckiDepartment of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.
A M CoutinhoLaboratory and Division of Nuclear Medicine (LIM-43), Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo, Brazil.
R NitriniDepartment of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.
M S YassudaDepartment of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/25000-1
6 · The paper itself

Abstract

The Short-Term Memory Conjunctive Binding (STMCB) test assesses the ability to maintain integrated shape-colour associations in memory. It has been applied to detect Alzheimer's disease (AD) across the continuum, from preclinical stages and subjective cognitive decline (SCD) to dementia. The objective of the present study was to examine whether the STMCB test can differentiate individuals at very early stages of AD from controls. The sample included 67 participants with normal performance on standard neuropsychological tests. Participants were classified as controls or as having SCD based on self-reported memory complaints. Twenty-three controls and 44 individuals with SCD completed the STMCB test. All individuals also underwent a comprehensive neuropsychological evaluation, amyloid ([

Indexed as

BrainCognitive DysfunctionMemory, Short-TermPositron-Emission TomographyAgedAged, 80 and overAniline CompoundsBenzothiazolesBiomarkersFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeuropsychological TestsThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsBenzothiazolesBiomarkersFluorodeoxyglucose F18ThiazolesAlzheimer’s diseaseBiomarkersCognitive markerConjunctive bindingMemory bindingSubjective cognitive decline

Identifiers

PMID41615512
PMCPMC12858614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.